287 related articles for article (PubMed ID: 24495125)
1. Long-term survival of dogs with adrenal-dependent hyperadrenocorticism: a comparison between mitotane and twice daily trilostane treatment.
Arenas C; Melián C; Pérez-Alenza MD
J Vet Intern Med; 2014; 28(2):473-80. PubMed ID: 24495125
[TBL] [Abstract][Full Text] [Related]
2. A comparison of factors that influence survival in dogs with adrenal-dependent hyperadrenocorticism treated with mitotane or trilostane.
Helm JR; McLauchlan G; Boden LA; Frowde PE; Collings AJ; Tebb AJ; Elwood CM; Herrtage ME; Parkin TD; Ramsey IK
J Vet Intern Med; 2011; 25(2):251-60. PubMed ID: 21352377
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the survival times of dogs treated with mitotane or trilostane for pituitary-dependent hyperadrenocorticism.
Barker EN; Campbell S; Tebb AJ; Neiger R; Herrtage ME; Reid SW; Ramsey IK
J Vet Intern Med; 2005; 19(6):810-5. PubMed ID: 16355673
[TBL] [Abstract][Full Text] [Related]
4. Comparison of non-selective adrenocorticolysis with mitotane or trilostane for the treatment of dogs with pituitary-dependent hyperadrenocorticism.
Clemente M; De Andrés PJ; Arenas C; Melián C; Morales M; Pérez-Alenza MD
Vet Rec; 2007 Dec; 161(24):805-9. PubMed ID: 18083978
[TBL] [Abstract][Full Text] [Related]
5. Medical management of pituitary-dependent hyperadrenocorticism: mitotane versus trilostane.
Reine NJ
Clin Tech Small Anim Pract; 2007 Feb; 22(1):18-25. PubMed ID: 17542193
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 2 Doses for ACTH Stimulation Testing in Dogs Suspected of or Treated for Hyperadrenocorticism.
Aldridge C; Behrend EN; Kemppainen RJ; Lee-Fowler TM; Martin LG; Ward CR; Bruyette D; Pannu J; Gaillard P; Lee HP
J Vet Intern Med; 2016 Sep; 30(5):1637-1641. PubMed ID: 27425787
[TBL] [Abstract][Full Text] [Related]
7. Old or new? A comparison of mitotane and trilostane for the management of hyperadrenocorticism.
Griffies JD
Compend Contin Educ Vet; 2013 May; 35(5):E3. PubMed ID: 23677783
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of occult hyperadrenocorticism with mitotane but not trilostane in a dog.
Park SM; Kim KB; Song WJ; Youn HY
Vet Med Sci; 2021 Jul; 7(4):1150-1153. PubMed ID: 33755348
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy of trilostane administered twice daily in dogs with pituitary-dependent hyperadrenocorticism.
Alenza DP; Arenas C; Lopez ML; Melian C
J Am Anim Hosp Assoc; 2006; 42(4):269-76. PubMed ID: 16822765
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Survival Times for Dogs with Pituitary-Dependent Hyperadrenocorticism in a Primary-Care Hospital: Treated with Trilostane versus Untreated.
Nagata N; Kojima K; Yuki M
J Vet Intern Med; 2017 Jan; 31(1):22-28. PubMed ID: 27906457
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: twice daily versus once daily.
Arenas C; Melián C; Pérez-Alenza MD
J Vet Intern Med; 2013; 27(6):1478-85. PubMed ID: 24118316
[TBL] [Abstract][Full Text] [Related]
12. Hyperadrenocorticism: treating dogs.
Brown CG; Graves TK
Compend Contin Educ Vet; 2007 Mar; 29(3):132-4, 136, 138 passim; quiz 144-5. PubMed ID: 17726933
[TBL] [Abstract][Full Text] [Related]
13. Effect of trilostane and mitotane on aldosterone secretory reserve in dogs with pituitary-dependent hyperadrenocorticism.
Reid LE; Behrend EN; Martin LG; Kemppainen RJ; Ward CR; Lurye JC; Donovan TC; Lee HP
J Vet Intern Med; 2014; 28(2):443-50. PubMed ID: 24400747
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of twice-daily lower-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism.
Feldman EC
J Am Vet Med Assoc; 2011 Jun; 238(11):1441-51. PubMed ID: 21627507
[TBL] [Abstract][Full Text] [Related]
15. Comparison of adrenocorticotropic hormone stimulation test results started 2 versus 4 hours after trilostane administration in dogs with naturally occurring hyperadrenocorticism.
Bonadio CM; Feldman EC; Cohen TA; Kass PH
J Vet Intern Med; 2014; 28(4):1239-43. PubMed ID: 24863172
[TBL] [Abstract][Full Text] [Related]
16. Update on the use of trilostane in dogs.
Lemetayer J; Blois S
Can Vet J; 2018 Apr; 59(4):397-407. PubMed ID: 29606727
[TBL] [Abstract][Full Text] [Related]
17. Comparison of mitotane treatment for adrenal tumor versus pituitary-dependent hyperadrenocorticism in dogs.
Feldman EC; Nelson RW; Feldman MS; Farver TB
J Am Vet Med Assoc; 1992 Jun; 200(11):1642-7. PubMed ID: 1320600
[TBL] [Abstract][Full Text] [Related]
18. Effect of trilostane on hormone and serum electrolyte concentrations in dogs with pituitary-dependent hyperadrenocorticism.
Griebsch C; Lehnert C; Williams GJ; Failing K; Neiger R
J Vet Intern Med; 2014; 28(1):160-5. PubMed ID: 24341822
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of low- and high-dose trilostane treatment in dogs (< 5 kg) with pituitary-dependent hyperadrenocorticism.
Cho KD; Kang JH; Chang D; Na KJ; Yang MP
J Vet Intern Med; 2013; 27(1):91-8. PubMed ID: 23167780
[TBL] [Abstract][Full Text] [Related]
20. Medical treatment of hyperadrenocorticism in the dog.
Braddock JA
Aust Vet J; 2003; 81(1-2):31-3. PubMed ID: 15084005
[No Abstract] [Full Text] [Related]
[Next] [New Search]
